Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Real-Life Experience of Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndrome Patients

Blood (2024) 144 (Supplement 1): 6737.

https://doi.org/10.1182/blood-2024-202478

Published: 2024

Journal Articles

High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity

Pinelopi Vryttia, Konstantina Theoharaki, Christina Apostolopoulou, Georgia Tzafa, Aggeliki Kondi, Eugenia Kazolia, Elina Vassilakou, Sotiris Karapatakis, Ioannis V Kostopoulos, Ourania Tsitsilonis, Anthi Bouchla, Sotirios G. Papageorgiou, Thomas Thomopoulos, Vasiliki Pappa, Marianna Antonelou

Blood (2024) 144 (Supplement 1): 1083.

https://doi.org/10.1182/blood-2024-209593

Published: 2024

Journal Articles

Illness Perceptions and Heath Related Quality of Life in Patients with Primary Immune Thrombocytopenia

Christina E Lekarakou, Antonios Bertsias, Panagiotis T Diamantopoulos, Marina Mantzourani, Anthi Bouchla, Sofia Chatzileontiadou, Peggy Kanellou, Athanasios Gakopoulos, George Katrinakis, Maria Psyllaki, Vasiliki Pappa, Maria Papaioannou, Dimitra Liapi, Sosana Delimpasi, Helen A Papadaki, George Koulierakis, Charalampos G Pontikoglou

Blood (2024) 144 (Supplement 1): 7692.

https://doi.org/10.1182/blood-2024-204552

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Ioannis Ntanasis-Stathopoulos, Eirini Katodrytou, Evdoxia Hatjiharissi, Emmanouil Spanoudakis, Vasiliki Douka, Despina Fotiou, Vasiliki Labropoulou, Dimitra Dalampira, Vasiliki Spiliopoulou, Theodosia Papadopoulou, Dimitrios Christoulas, Panagiotis Malandrakis, Anthi Bouchla, Vasiliki Pappa, Efstathios Kastritis, Evangelos Terpos, Meletios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6988.

https://doi.org/10.1182/blood-2024-206900

Published: 2024

Journal Articles

Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Blood (2024) 144 (Supplement 1): 4673.

https://doi.org/10.1182/blood-2024-203776

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Distinct Role of STAT3 and STAT5 Factors in MDS and AML

Eirini Sofia Fasouli, Konstantina Giavi, Charikleia Makri, Leonid Bystrykh, Anthi Bouchla, Emmanouil Athanasiadis, Giannis Vatsellas, Vasiliki Pappa, Eleni Katsantoni

Blood (2023) 142 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2023-185823

Published: 2023

Journal Articles

Myelodysplastic Syndrome Red Blood Cell Physiology Abnormalities and Their Correlation with Disease Risk and Therapeutic Interventions

Pinelopi Vryttia, Konstantina Theocharaki, Eugenia Kazolia, Christina Apostolopoulou, Anthi Bouchla, Ioannis V Kostopoulos, Sotirios Papageorgiou, Georgia Tzafa, Ourania Tsitsilonis, Vasiliki Pappa, Marianna Antonelou

Blood (2023) 142 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2023-186143

Published: 2023

Journal Articles

A Novel Variant of the CYCS Gene Alters Apoptosis of Megakaryocytes in a Family with Thrombocytopenia

Konstantina Giavi, Stavros Glentis, Anthi Bouchla, Anastasia Apostolidou, Nikolaos M. Marinakis, Antonis Kattamis, Eleni Katsantoni, Vasiliki Pappa

Blood (2023) 142 (Supplement 1): 5409.

https://doi.org/10.1182/blood-2023-186060

Published: 2023

Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Blood (2023) 142 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2023-178009

Published: 2023

Journal Articles

The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine

Paraskevi Miltiades, Eleytheria Labrianidou, Theodoros P. Vassilakopoulos, Sotirios G Papageorgiou, Athanasios G. Galanopoulos, Sofia Vakalopoulou, MD, Ass.Prof.Hematology, Vassilia Garypidou, Evangelia Nakou, Emmanuil Spanoudakis, Maria Papaioannou, Helen A. Papadaki, MD, PhD, Vasiliki Pappa, Konstantinos Tsatalas, Ioannis Kotsianidis, MD, PhD

Blood (2012) 120 (21): 3795.

https://doi.org/10.1182/blood.V120.21.3795.3795

Published: 2012

Journal Articles

Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine

Paraskevi Miltiades, Irene Bouchliou, Evangelia Nakou, Emmanuil Spanoudakis, Sotirios Papageorgiou, Vasiliki Pappa, Maria Papaioannou, Eleytherios Moustakidis, Sofia Vakalopoulou, Vasilia Garipidou, Konstantinos Tsatalas, Ioannis Kotsianidis

Blood (2010) 116 (21): 2921.

https://doi.org/10.1182/blood.V116.21.2921.2921

Published: 2010

NARROW

Real-Life Experience of Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndrome Patients

High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity

Illness Perceptions and Heath Related Quality of Life in Patients with Primary Immune Thrombocytopenia

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Distinct Role of STAT3 and STAT5 Factors in MDS and AML

Myelodysplastic Syndrome Red Blood Cell Physiology Abnormalities and Their Correlation with Disease Risk and Therapeutic Interventions

A Novel Variant of the CYCS Gene Alters Apoptosis of Megakaryocytes in a Family with Thrombocytopenia

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine

Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only